Pharmaceutical Sector

Australian Court orders Reckitt Benckiser to Pull Its Nurofen Pain Relief Products from Market

Australian Court orders Reckitt Benckiser to Pull Its Nurofen Pain Relief Produc

According to a recent ruling by an Australian Federal Court, Reckitt Benckiser has misled consumers by marketing identical products for different types of pain. The court has even asked the British form to remove its Nurofen pain relief products from the market.

The court said in a statement that the Nurofen Back pain, Migraine Pain and Tension Headache products were found to be identical, and Reckitt Benckiser was involved in cheating its customers.

A pharmacist at Priceline Pharmacy's Sydney city store told Reuters, “We have known for years that they are all the same. We have been advising our customers to go for the standard painkiller which is cheaper”.

America’s Most Hated Man Martin Shkreli to raise Prices of another Life-saving Medicine

America’s Most Hated Man Martin Shkreli to raise Prices of another Life-saving

Martin Shkreli, the bad boy of pharma who is also known as most hated man in the US, gives another reason to point fingers at him. In a video, Shkreli can be seen talking about a fatal brain condition. According to Shkreli, only three hundred individuals are with the disease.

Shkreli, who has bought a majority share in KaloBios Pharmaceuticals, gave the statement while announcing about a new drug. The 32-year-old co-founder of the hedge fund MSMB Capital Management said he has a new drug capable of treating the deadly disease. “But it’s hard to sell a drug for 300 people, to go through the process. You have to charge a lot per person to make it a viable product”, Shkreli added.

Alexion’s Drug Kanuma receives FDA Approval to Treat LAL-D

Alexion’s Drug Kanuma receives FDA Approval to Treat LAL-D

The US Food and Drug Administration (FDA) gave a green signal to Alexion Pharmaceutical Inc's drug on Tuesday to treat rare and fatal genetic disorder. On the same day, shares of the company were up 4.5% at $187.22.

Kanuma, enzyme-replacement therapy of Cheshire headquartered Alexion, received approval of European Union in September this year to treat people with acid lipase deficiency (LAL-D), a medical condition that could result into heart disease, liver failure and even early death.

German drugmaker Merck’s experimental cancer medicine evofosfamide fails in last stage of clinical tests

German drugmaker Merck’s experimental cancer medicine evofosfamide fails in last

German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.

On Monday, Darmstadt, Germany-based Merck said in a statement that the medicine wasn’t helpful for patients, having pancreatic cancer or soft-tissue sarcoma live longer when taken along with chemotherapy.

Merck has faced a blow by the decision as the drugmakerhas sought new drugs for boosting its lineup, but not a dramatic one. The drugmaker said that it has confidence in its pipeline and is planning to re-allocate resources to other main programs.

Turing’s chief commercial officer says ‘No patient needing Daraprim will ever be denied access’

Turing’s chief commercial officer says ‘No patient needing Daraprim will ever

The pharmaceutical company that hiked the price of a drug used for the treatment of AIDS and cancer by 5,000% is cutting the price. It is going to charge hospitals by 50%. Yesterday, NY and Zug, Switzerland-based Turing Pharmaceuticals LLC announced a 50% cut in its prices for toxoplasmosis drug Daraprim.

In a statement, the company said, “After talking with doctors, patients, and patient advocacy groups and considering the ongoing patient assistance programs, Turing recognized that the place they could have the biggest impact on Daraprim cost – and ultimately cost savings to patients was in hospitals”.

Gilead Sciences Gave Profit More Importance than Hepatitis C Cure

Gilead Sciences Gave Profit More Importance than Hepatitis C Cure

Ron Wyden of Oregon and his Republican wingman Chuck Grassley of Iowa recently revealed the findings of their 18-month long investigation into Gilead Sciences and its Hepatitis C Drug Sovaldi.

The investigators after examining the internal documents of more than 20,000 pages and carrying out dozens of interviews with the company’s executives found that Gilead Sciences tried to make money out of its Hepatitis C drug Sovaldi.

The report provides the most transparent look ever into pricing decisions in the modern drug business. It shows that Gilead deliberatively set price for Sovaldi after checking the basis of clinical attributes, value determinations, market research and cost of presently available products in the market.

New Leukemia Drug reduces Death Risk More Effectively than Chemo for Untreated Patients

New Leukemia Drug reduces Death Risk More Effectively than Chemo for Untreated

A leukemia drug of Johnson & Johnson and AbbVie has been found significantly reducing the risk of death and disease compared with chemotherapy in patients with leukemia. The drug, Imbruvica, has paved the way for its extended version which could be more beneficial.

A report released by researchers on Sunday showed that the drug has been found decreasing the risk of death in a trial of 269 participants with chronic lymphocytic leukemia (CLL). All the study participants wereaged 65 and older. Imbruvica decreased death risk by about 85% compared with the chemotherapy chlorambucil, as per the report.

Researchers to begin testing Metformin as an anti-aging drug in a clinical trial next year

Researchers to begin testing Metformin as an anti-aging drug in a clinical trial

Researchers are going to start testing Metformin, a medication used for the treatment of diabetes, as an anti-aging drug in a clinical trial in the coming year. When the medication is used to treat type 2 diabetes, the drug cuts the glucose produced in the liver, but according to researchers it could also slow down the aging process in individual cells by boosting the level of oxygen released into every cell.

The research has suggested that cutting the biological effects of aging is indicative of the probability of longer lifespans, staving off aging-related diseases such as Parkinson's and Alzheimer's and possibly would allow humans to live their lives till their 110s or 120s.

New Investigation Unveils Story Behind Gilead Sciences Move to Increase Price of a Hepatitis C Drug

New Investigation Unveils Story Behind Gilead Sciences Move to Increase Price

According to a Senate Finance Committee investigation report, executives of Gilead Sciences were already aware in 2013 that their plan of increasing the price of a new hepatitis C drug will give rise to public outrage. Despite knowing this fact, the company went forward with the strategy to increase price of the drug, it showed.

Gilead Sciences got federal approval for its drug Sovaldi in late 2013. The company settled the price of $84,000 for a 12-week course of treatment.

According to the internal documents, the company knew that the high price will deliver the right balance: i.e. value to shareholders while also not so high that insurers would ‘hinder patient access to uncomfortable levels’.

Planned Parenthood sues Texas for kicking it out of state’s Medicaid program

Planned Parenthood sues Texas for kicking it out of state’s Medicaid program

Texas’ plans of reducing Medicaid funding have gone up following a series of video releases wherein Planned Parenthood staff was seen doing discussion over sales of fetal tissue and price negotiations after procedures for abortion. A judge has ordered that Planned Parenthood clinics could remain open in Louisiana.

Planned Parenthood said in their statement, it was wrong to downplay the significant reproductive health and preventive health services provided by them.

The lawsuit stated that the provider network available to Texas Medicaid patients has declined in recent years to only over 30% of practicing physicians. Federal dollars awarded via Medicaid would also come to an end with the order. Texas is among the 5 states that have tried black funding for Planned Parenthood.

Turing Pharmaceuticals reneges on its pledge to cut $750-per-pill price

Turing Pharmaceuticals reneges on its pledge to cut $750-per-pill price

Weeks after facing criticism from doctors, patients and other drugmakers for increasing the price of a life-saving medicine over five times, Turing Pharmaceuticals has reneged on its promise of cutting the $750-per-pill price.

The small biotech company has instead decided to cut what it charges hospitals for its parasitic infection treatment, Daraprim, by up to 50%. Most of the co-payments by patients will be capped at $10 or less per month, however, insurers are going to be stuck with the bulk of the $750 tab. This will drive up insurance costs and future treatment.

Turing Pharmaceuticals Fails to Keep Its Pledge to Cut Cost Of Daraprim

Turing Pharmaceuticals Fails to Keep Its Pledge to Cut Cost Of Daraprim

Turing Pharmaceuticals, a fully integrated biopharmaceutical company that focuses majorly on patients with unmet medical needs refuses to cut down the price of its lifesaving drug Daraprim.

It has come into notice that the company is reducing the price for hospitals by up to 50 percent for Daraprim, a drug that treats toxoplasmosis, a rare parasitic infection that mainly strikes pregnant women and HIV patients.

CEO Martin Shkreli on Tuesday announced that the company officials decided that kit was more important to cut the cost of the medicine to hospitals, according to The New York Times.

Daraprim is actually a 62-year-old pill and its patent has expired decades ago. Carlos del Rio, chairman of the HIV Medicine Association said changes made by Turing are just ‘window dressing’.

Planned Parenthood’s presence in Texas has reduced significantly

Planned Parenthood’s presence in Texas has reduced significantly

According to Texas, it has been successfully able rebuild a safety net without Planned Parenthood. But according to independent health experts, the state will take a long time before it can reach a level when Planned Parenthood was a vital part of its family planning efforts.

The government has come up with the new system after four years of cutting funding for Planned Parenthood. The state's retooled family-planning programs are even considered as a model for Republicans in Congress who want to end funding for Planned Parenthood at a national level.

As per the data provided by Texas health officers, the new programs has covered 317,393 women in 2014, which is almost equivalent to 320,044 women covered in 2010 when the funding was not cut from Planned Parenthood.

Independent panel says Sugammadex is safe and effective enough to warrant approval

Independent panel says Sugammadex is safe and effective enough to warrant approv

An independent panel to the US Food and Drug Administration (FDA) has said that Merck & Co's drug to reverse the effects of muscle relaxants used in surgery is safe and quite effective to warrant approval.

The chemical name of the drug is sugammadex. FDA has repeatedly rejected it over concerns related to potentially dangerous allergic reactions, even though the drug has the approval in over 75 countries.

The drug was acquired by the company when it purchased the US drugmaker Schering Plough, which created the drug sugammadex in 2009.

Gilead Sciences’ Tablet Genvoya gets FDA Approval for Treatment of HIV-1 Infection

Gilead Sciences’ Tablet Genvoya gets FDA Approval for Treatment of HIV-1

Gilead Sciences Inc. recently announced that the US Food and Drug Administration (FDA) has given final approval to its single tablet regimen Genvoya for the treatment of HIV-1 infection.

As per the makers of the drug, Genvoya is a full treatment of HIV-1 infection. It could be used in adults, in pediatric patients with 12 years of age and older that have no antiretroviral treatment history.

The drug could also replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen for at least six months. These patients should not have any history of treatment failure and there should be no known substitutions associated with resistance to the individual components of Genvoya.

US Senate panel launches a bipartisan probe into drug pricing

US Senate panel launches a bipartisan probe into drug pricing

On Wednesday, a US Senate panel launched a bipartisan probe into pharmaceutical pricing in quest of documents from four drugmakers, including Valeant Pharmaceuticals and Turing Pharmaceuticals, the companies that were a part of a controversy over price hikes of lifesaving drugs.

As per a statement from the panel's Republican Chairwoman Susan Collins and Claire McCaskill, its top Democrat, the Senate's Special Committee on Aging has also asked for information from Retrophin Inc and Rodelis Therapeutics.

Furthermore, on Wednesday, a US House of Representatives investigative committee's Democratic members asked Republicans for calling a vote to subpoena Valeant and Turing.

Woman stops Planned Parenthood protest with words ‘yeast infections’

Woman stops Planned Parenthood protest with words ‘yeast infections’

On Sunday, Mary Numair discovered how yelling at the top of your raspy voice about yeast infections can disperse a mass of Planned Parenthood protesters. Mary found so in a spontaneous single-woman counter protest in front of the center of the organization in Northeast Portland.

When she repeatedly chanted ‘YEAST IN-FECTIONS’, all parents and children, who were toting signs declaring ‘ABORTION IS MURDER’ rushed away.

The 29-year-old woman, Numair, of Southeast Portland, tweeted about her triumph. Her tweet soon went viral. Her story was picked up by Buzzfeed. Slate called her ‘brave’ and her protest was declared ‘awesome’ by Huffington Post. Even the British media picked up the news.

Planned Parenthood dubs record request politically motivated

Planned Parenthood dubs record request politically motivated

Planned Parenthood is having a really bad time. Now, the fight over Medicaid funding for Planned Parenthood has moved to Texas, where Gov. Greg Abbott has asked to end the funding for the organization. Texas health department investigators also reached Planned Parenthood health centers in different places to see documents.

Planned Parenthood South Texas has been asked to provide five years of records, which have any case of patient who has undergone abortion and any part of the fetus has been preserved for research use and also, has been billed to Medicaid.

Costly Turing Pharmaceuticals drug faces competition from Imprimis

Costly Turing Pharmaceuticals drug faces competition from Imprimis

Last month, Turing Pharmaceuticals led to a nationwide outrage and government investigations after it hiked the price of Daraprim, a drug for treating AIDS and cancer, from $13.50 a capsule to $750. San Diego’s biomedical company Imprimis Pharmaceuticals has introduced a competitor to the medication for $1 a capsule this week.

Imprimis is looking forward to follow the same strategy to undercut the sale of other generic drugs sold at quite more than their manufacturing cost. Alike Daraprim, the medications will be used in niche markets that so far haven't faced much competition.

FDA Advisory Panel endorses Approval of Lesinurad for Gout Patients

FDA Advisory Panel endorses Approval of Lesinurad for Gout Patients

AstraZeneca, multinational pharmaceutical and Biologics Company, announced today that the US Food and Drug Administration’s (FDA) Arthritis Advisory Committee (AAC) voted 10-4 to put forward for consent of lesinurad 200 mg tablets, which are used in the treatment of hyperuricemia linked with gout, in amalgamation with a xanthenes oxidase inhibitor (XOI).

The AAC assessed desired results from the crucial Phase-III amalgamation therapy program trials, which was the largest clinical data set of gout patients treated along with urate-lowering therapy.

All 10 supporters of the drug, lesinurad, passed their voting by compelling the FDA to ask AstraZeneca for studies after lesinurad launch to measure its long-lasting effectiveness and safety.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content